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SCN2APlease cite this article as: Schwarz N et al.,
Paediatric Neurology, https://doi.org/10.101have recently described SCN2A-associated episodic ataxia (EA). Our study identifies its
broader clinical and genetic spectrum, and describes pharmacological approaches.
Results:We report 21 patients with SCN2A-associated EA, of which 9 are unpublished cases.
The large majority of patients present with epileptic seizures (18/21, 86%), often starting
within the first three months of life (12/18, 67%). In contrast, onset of episodic ataxia ranged
from 10 months to 14 years of age. The frequency of EA episodes ranged from brief, daily
events up to 1e2 episodes per year each lasting several weeks. Potential triggers include
minor head traumas and sleep deprivation. Cognitive outcome is favorable in most pa-
tients with normal or mildly impaired cognitive development in 17/21 patients (81%). No
clear genotypeephenotype correlations were identified in this cohort. However, two
mutational hotspots were identified, i.e. 7/21 patients (33%) harbor the identical pathogenic
variant p.A263V, whereas 5/21 (24%) carry pathogenic variants that affect the S4 segment
and its cytoplasmic loop within the domain IV. In addition, we identified six novel path-
ogenic variants in SCN2A. While acetazolamide was previously reported as beneficial in
SCN2A-associated EA in one case, our data show a conflicting response in 8 additional
patients treated with acetazolamide: three of them profited from acetazolamide treatment,
while 5/8 did not.
Conclusions: Our study describes the heterogeneous clinical spectrum of SCN2A-associated
EA, identifies two mutational hotspots and shows positive effects of acetazolamide in
about 50%.
© 2019 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights
reserved.1. Introduction
The implementation of next generation sequencing methods
has led to the identification of numerous ion channel genes as
cause of neurologic disorders including epilepsy, autism, intel-
lectual disability or ataxia. The eight forms of episodic ataxia
(EA) described so far belong to the group of hereditary ataxia.
Type 1 episodic ataxia (EA1) presents with episodes of general-
ized ataxia triggered by stress or emotions. Pathogenic variants
in KCNA1, encoding the potassium channel KV1.1, are causative
for theepisodes,which last seconds tominutes.1 Episodic ataxia
type2 (EA2) ischaracterizedbyacetazolamide-responsiveataxic
episodes,which last hours todays andare causedbypathogenic
variants in CACNA1A, encoding the calcium channel CaV2.1.
2
Episodic ataxia types 3e8 are very rare and are only described
in individual case studies.
SCN2A encodes the alpha subunit of the voltage gated
neuronal sodium channel NaV1.2.
3 Pathogenic variants in
SCN2A have been associated with a broad spectrum of epi-
lepsy subtypes potentially accompanied by intellectual
disability and/or autistic traits.4 In addition, few cases of
SCN2A-associated EA were reported.5e11 These few reports do
not allow the establishment of genotypeephenotype correla-
tions, which would be a prerequisite for the implementation
of targeted/precision medicine approaches.12
SCN2A-associated EA was first described in 20108 with the
report of a SCN2A gain-of-function pathogenic variant in a
patient with neonatal-onset seizures. While seizures were
well controlled and only occurred sporadically from 18
months of age onwards, the boy developed episodes of ataxia.
Since then, 11 additional patients were reported.5e7,9e11Clinical and genetic spe
6/j.ejpn.2019.03.001We collected all available patients with SCN2A-associated
EA within an international collaboration to analyze the clin-
ical course of unpublished and previously published patients.
We here describe the clinical course, genetic background and
pharmacological attempts in a total of 21 patients with
SCN2A-associated EA.2. Methods
Patients with SCN2A-associated EA were collected within an
International collaboration with co-authors of our previously
published SCN2A case study4 and other research networks
including NETRE (¼ network therapy rare epilepsies). An ac-
cording questionnaire was generated and filled out by all co-
authors. The questionnaire enquired inheritance mode, de-
tails regarding episodic ataxia such as age at onset, specific
symptoms and clinical course during EA episodes, duration
and frequency of episodes, and treatment for ataxia. In addi-
tion, details regarding epilepsy (if existing) such as onset of
epilepsy, seizure types and anti-convulsive treatments were
collected. Cognitive status and assessment of psychomotor
development of the patients was asked for. Written informed
consent for research and publication was obtained from the
families. All procedures were in accordance with the ethical
standards of the institutional and/or national research com-
mittee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards. Genetic testing
for pathogenic variants in SCN2Awas performed according to
the evaluation by the treating physicians in either a research
or a diagnostic laboratory. Inclusion criteria were the exis-
tence of pathogenic or likely pathogenic variants in SCN2Actrum of SCN2A-associated episodic ataxia, European Journal of
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y x x x ( x x x x ) x x x 3according to ACMG standards and guidelines13 as well as a
phenotype of episodic ataxia. Exclusion criteria were the ex-
istence of pathogenic or likely pathogenic variants in genes
that have previously been associated with episodic ataxia.
Tumors or malformations of the posterior fossa as a potential
origin for the development of ataxia were excluded by cranial
imaging. Our study was focused on patients with an episodic
course of ataxia. Patients with persistent ataxia (e.g., devel-
oping under anticonvulsant therapy) were excluded in this
study.3. Results
A total of 21 patients with SCN2A-associated EAwas collected.
Nine patients were not previously published (Patients 1 to 9,
Table 1). We collected updates regarding the clinical course of
the twelve previously published patients (Patients 10 to 21,
see Table 2). Subordinated clinical data are shown in
Supplementary Table 1 (Suppl. Table 1). Themale/female ratio
was 13:8. Age at last visit reported here differed between 1.5
and 31 years.
3.1. Episodic ataxia: phenotype
While epileptic seizures mostly occurred during the first three
months of life (12/18), the first episode of ataxia never
occurred before 10 months (Patient 2) (see Fig. 1). Much later
onsets up to 14 years (Patient 20) were also noticed. We
excluded a few reported patients with permanent ataxia,
which has been described as potential secondary effect of
chronic pharmacological treatment with phenytoin and other
anti-convulsive medications.14,15
The frequency of episodes differs between daily in two
cases (Patients 1 and 18), weekly to monthly in most cases
(Patients 2e4, 6e13, 19e21), and at most 1e3 episodes every
year in Patients 5 and 14e17 (Tables 1 and 2).
The duration of each EA episode is heterogeneous between
patients: while most patients showed episodes lasting mi-
nutes to maximum several hours (Patients 1e4, 6e13, 18,19),
periods lasting days up to weeks were also reported (Patients
5, 14e16). The three familial cases previously published by us5
obviously present a peculiar phenotype, characterized by the
lack of seizures, a relatively low frequency of episodes (1e2
per year) and unusually long durations of each episode
(around 3 weeks each). This will be further discussed below.
As extensively discussed in the context of (genetic) epi-
lepsies,16 paroxysmal events can be triggered by external
factors such asminor head injuries, sleep deprivation, alcohol
ingestion, photostimulation, and others. Whether immuno-
logical processes such as vaccinations might trigger the onset
and occurrence of paroxysmal events including epileptic sei-
zures is still under debate.17
In our cohort, several triggers of EA episodes were
identified (Tables 1 and 2). These included sensory stimuli,
e.g., a sudden noise and vibrations of the body. In addition,
the menstruation cycle triggered EA episodes in one patient
(Patient 6). Of note, two of a total of four EA episodes
in Patient 14 were temporally associated with prior
vaccinations.5Please cite this article as: Schwarz N et al., Clinical and genetic spe
Paediatric Neurology, https://doi.org/10.1016/j.ejpn.2019.03.0013.2. Epilepsy in patients with SCN2A associated
episodic ataxia
Pathogenic variants in SCN2A can lead to a spectrum of
epileptic seizures.4 Previous reports of SCN2A associated EA
described cases with co-occurrence of seizures,6e11 but
absence of epilepsy in three familial cases was also reported.5
In our study, these three previously reported familial cases
remained the only ones within our cohort that did not expe-
rience epileptic seizures,5 while every other patient did (18/21,
86%). In most cases with epilepsy, seizures started within the
first three months of life (12/18, 67%), with neonatal-onset
seizures in 9/12 (75%) patients. Given the early onset of
epileptic seizures, these cases are presumably based on
pathogenic gain-of-function variants in SCN2A.4,18 Therefore,
sodium channel blockers and phenytoin in particular were the
anti-convulsive medications of choice. Eleven out of 18 pa-
tients still required anti-convulsive treatment at the last
recorded visit, all of them received a sodium channel blocker.
Five patients did not receive any anti-convulsive medication
at the last visit.
3.3. Pharmacological treatment of episodic ataxia
While early-onset SCN2A-associated epileptic seizures may
well respond to treatment with sodium channel blockers and
phenytoin in particular,4 the best treatment of SCN2A-asso-
ciated EA has yet to be determined. Treatment with the car-
bonic anhydrase inhibitor acetazolamide is well established
for CACNA1A-associated episodic ataxia type 219 and has once
been reported to be successful for SCN2A-associated EA.7
At last visit, 11 of the 18 patientswith epileptic seizures still
received anti-convulsive treatment, which included a sodium
channel blocker in all cases. In almost all cases (9/11), treat-
ment with sodium channel blockers (for dosages see Tables 1
and 2) did not have any positive effect on episodic ataxia.
There were two exceptions (Patient 5 and 8). In patient 5,
carbamazepine e initially given as anti-convulsive drug e led
to a strong improvement of ataxic and dysarthric episodes, i.e.
a reduction in the frequency fromweekly episodes to sporadic
events. This was a case with a very late onset of EA at 6 years
of age. In patient 8, levetiracetam led to a moderate reduction
of the EA frequency.
As to patient 11, about 6 months after withdrawal of val-
proic acid e that had been initiated for his epilepsy and was
then stopped due to seizure freedom e EA episodes increased
from 2 to 3 per year to 2 per month, while each episode
became longer (from 1e2 min to 30e60 min each). It remains
unclearwhether this observation reflects a causal relationship
or whether this was a temporal co-incidence. Positive effects
of valproic acid treatment on EA were not reported in any
other patient within our cohort.
Acetazolamide was previously reported as beneficial in a
single case with SCN2A-associated EA,7 this case is part of our
study (Patient 17). Thus, acetazolamide was now tried as po-
tential treatment in eight other patients within our cohort.
The dosage ranged from 4.3mg/kg body weight/day (Patient 1)
to 30 mg/kg body weight/day (Patient 12). Five of these eight
patients did not profit from acetazolamide treatment. Adverse
events were not reported. However, one patient (Patient 19)ctrum of SCN2A-associated episodic ataxia, European Journal of
Table 1 e Unpublished cases of patients with SCN2A associated episodic ataxia.
Patient 1 Patient 2 Patient 3
(sister of P4)
Patient 4
(brother of P )
Patient 5
Gender, age F, 11y F, 2y F, 3y M, 7y M, 8y
Pathogenic variant, inheritance c.2960G > T
p.S987I
de novo
c.4952T > G
p.F1651C
de novo
c.788C > T
p.A263V
inherited from father
c.788C > T
p.A263V
inherited from fat r
c.3754A > G
p.I1252V
de novo
Age at ataxia onset 4y 6m 10m 18m 3y 6y
Frequency of episodes Daily episodes since
onset of ataxia
2 per month 4 per month 2 per month 3 per year
Duration of single
episode of ataxia
1e1.5 min 12e24 h Several hours 1e12 h 24e48 h
Triggers for ataxia Whole body movement
(e.g., after a car trip)
None None None None
Treatment of ataxia: specific/AED Acetazolamide (4.3 mg/kg/d) None/phenytoin as AED None/phenytoin as AED None/phenytoin a AED None/carbamazepine as AED
Effect of treatment on
ataxia: specific/AED
None e/None e/None e/None CBZ: strong improvement
of ataxic/dysarthric episodes
(from weekly freq. to sporadic
episodes)
Epilepsy Hemiclonic seizures þ apneas Generalized tonic
eclonic seizures
Generalized toniceclonic
seizures and complex-
partial seizures
Generalized tonice lonic
seizures and
complex-partial se ures
Complex partial seizures
Age at seizure onset First day of life 5th postnatal day 2m 10th postnatal day 6m
Current anti-epileptic
medication and dosage
None Phenytoin, 9.5 mg/kg/d Phenytoin, 6 mg/kg/d Phenytoin, 6 mg/k d Carbamazepine, 20 mg/kg/d
Cognitive status/development Normal Mild global developmental
delay; muscular hypotonia
Normal; Bayley-III: motor
delay; muscular hypotonia
Bayley-III: global d ay;
muscular hypoton
Mild global developmental
delay with delay of speech and motor delay
Patient 6 Patient 7 Pa nt 8 Patient 9
Gender, age F, 19y M, 16y M, 14y M, 5y
Pathogenic variant,
Inheritance
c.3973G > A
p.V1325I
inheritance unknown
c.788C > T,
p.A263V
mother tested: negative
father passed away
c.5311T > C
p.Y1771H
de novo
c.1028A > G
p.D343G
de novo
Age at ataxia onset 3y 2.5y 1y 6m 3y
Frequency of episodes Every 6e8 weeks, clusters with up
to 3/week possible
4e5 per month 4 per week 1 per month
Duration of single
episode of ataxia
Initially for 1e2days,
currently only minutes
Typically hours; currently
until he awakens next day
5 min Seconds emax. 1 min
Triggers for ataxia Menstruation cycle, sleep
deprivation, physical stress
Stress, excitement, poor sleep, fatigue None None
Treatment of ataxia:
Specific/AED
Carbamazepine (1050 mg/d), Sultiam,
oxcarbazepine, lamotrigine,
acetazolamide, topiramate
Acetazolamide
3  250 mg/oxcarbazepine 2  1200 mg
None/levetiracet and
perampanel as A
None/oxcarbazepine as AED
Effect of treatment
on ataxia: specific/AED
Information not available None e/levetiracetam: oderate
diminution of th requency
of episode of ata
e/
None
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Please cite this article as: Schwarz N et al., Clinical and genetic spe
Paediatric Neurology, https://doi.org/10.1016/j.ejpn.2019.03.001showed a major improvement regarding both the quantity
and quality of EA: frequency of episodes was reduced from
several daily episodes to 1e2 episodes per week, and the
severity of ataxia became milder during EA episodes since
acetazolamide treatment has been started. The current acet-
azolamide dosage in this patient is 21mg/kg body weight/day.
In addition, two further patients (Patient 20 and Patient
21) showed minor improvements under acetazolamide
treatment.
Taken together, acetazolamide might indeed have a
beneficial effect on EA episodes, yet around half of our pa-
tients did not profit from this treatment. As no adverse events
were reported, we suggest that acetazolamide should be tried
under close monitoring of serum bicarbonate levels.
3.4. Genetic findings and genotypeephenotype
correlations
As depicted in Fig. 2, the EA associated pathogenic SCN2A
variants are widespread among the NaV1.2 alpha subunit. Six
pathogenic variants were hitherto not described, i.e., p.D343G
(Patient 9) being located in the cytoplasmic loop between
domain I and domain II, p.S987I (Patient 1) in the cytoplasmic
loop between domain II and domain III, p.I1252V (Patient 5) in
the second segment of domain III and p.V1325I (Patient 6) in
the cytoplasmic loop between segment four and five of
domain III. The two further novel pathogenic variants were
p.F1651C (Patient 2), which is located in the cytoplasmic loop
between segments four and five of domain IV, and p.Y1771H
(Patient 8), which is located within segment six of domain IV.
There is one obvious mutational hotspot (p.A263V) that
affects the S5 segment of the domain I within the NaV1.2
alpha subunit e 7 out of 21 patients we describe harbored
this particular pathogenic variant. In addition, 5/21 patients
(24%) carry pathogenic variants that affect the S4 segment
and its cytoplasmic loop within the domain IV (Patients 2,
14e17).
The pathogenic variants mostly occurred de novo, yet
inherited variants in one family with three affected in-
dividuals (Patients 12e14), another family where the affected
father (patient 20) harbored the pathogenic variant that was
inherited to the daughter (patient 21) and one family with two
affected children (Patients 3 and 4) are also included. In the
latter cases, the father harbored the pathogenic variant that
was inherited to both children. The father himself was
healthy and did not show any neurologic abnormalities.4. Discussion
Our study describes the clinical course, genetic background
and pharmacological treatment approaches of SCN2A-asso-
ciated episodic ataxia. Despite a large heterogeneity within
the cohort, the majority of patients is characterized by similar
features: co-occurrence of epileptic seizures with neonatale/
early infantile seizures; favorable outcome with unimpaired
or only slightly impaired cognitive development at the time of
last visit; currently insufficient treatment alternatives for EA
with mostly lack of response to sodium channel blockers and
conflicting responses to acetazolamide.ctrum of SCN2A-associated episodic ataxia, European Journal of
Table 2 e Previously published cases of patients with SCN2A associated episodic ataxia.
Patient 10 Patient 11 Patient 12 Patient 13 Patient 14
Previously published Schwarz et al., 2016
(PMID: 26645390)
Schwarz et al., 2016
(PMID: 26645390)
Liao et al., 2010 (PMID: 20956790)
Schwarz et al., 2016 (PMID: 26645390)
Schwarz et al., 2016
(PMID: 26645390)
Fazeli et al., 2018
(PMID: 30165711)
Gender, age M, 6y F, 12y M, 18y M, 14y M, 3.5y
Pathogenic variant,
inheritance
c.788C > T
p.A263V
de novo
c.4565G > C/c.5644C > G
p.G1522A/p.R1882G
inherited/de novo
c.788C > T
p.A263V
de novo
c.5644C > G
p.R1882G
de novo
c.4949T > C, p.L1650P
inherited from equally
affected mother
Age at ataxia onset 15m 20m 1.5y 3.7y 12m
Frequency of episodes 1e2 per month 1e2 per week 3e4 per month 1 per month 4 within 2 years
Duration of single
episode of ataxia
Several hours to 1 day Rarely repeating over 2 h Several hours 30 min 3 weeks
Triggers for ataxia Vibrations None None None Potentially vaccinations
Treatment of ataxia:
specific/AED
None None Lamotrigine
2  200 mg/day
Lamotrigine
2  50 mg/day
Acetazolamide (30 mg/kg/d)
Effect of treatment
on ataxia: specific/AED
e e e/
None
e/50% reduction of episodes None
Epilepsy Bilateral tonic seizures
evolving into secondary
generalized toniceclonic
seizures e currently seizure free
Generalized toniceclonic
seizures e currently
seizure free
Generalized toniceclonic seizures
at age of 6.5 and 14 years;
Trigger for seizures: Fever,
infection, minor head trauma
Bilateral toniceclonic seizures
with reduced oxygen saturation
and unresponsiveness e
currently seizure free
No
Age at seizure onset Postnatal day 7 1m First day of life Postnatal day two e
Current anti-epileptic
medication and dosage
None None Lamotrigine (400 mg/day) Lamotrigine (100 mg/day) e
Cognitive status/development Development slightly retarded Normal Specific (visual and visuomotor)
cognitive dysfunction
Developmental delay of speech Lower normal range
Patient 15 Patient 16 Patient 17 Patient 18 Patient 19
Previously published Fazeli et al., 2018
(PMID: 30165711)
Fazeli et al., 2018
(PMID: 30165711)
Leach et al., 2016
(PMID: 27328862)
Johannesen et al., 2016
(PMID: 27159988)
Gorman et al., 2017
(PMID: 28065826)
Gender, age M, 1.5y F, 28y M, 8y F, 3y M, 5y
Pathogenic variant,
inheritance
c.4949T > C, p.L1650P
inherited from equally
affected mother
c.4949T > C, p.L1650P
unknown (parents not
available for testing)
c.217G > A,
p.G1634D
de novo
c.788C > T
p.A263V
de novo
c.788C > T
p.A263V
de novo
Age at ataxia onset 13m 3y 11m 13m 20m
Frequency of episodes 1 in total 4 within 15y Two in the first six years,
no ataxia at present
Daily episodes up to a
few per week
1 per 6 weeks
Duration of single
episode of ataxia
5 days to 3 weeks 3 weeks No information, since well
controlled on acetazolamide
Minutes to cluster of
max. 1 day
2e5 min, which recur in
clusters which last from 0.5 to 4 h
Triggers for ataxia None None Fever, trauma Fright (sudden noise,
a simple falling), pain
None
Treatment for ataxia Acetazolamide
(20 mg/kg/d)
None Acetazolamide (18 mg/kg/d) None Acetazolamide (21 mg/kg/day)
Effect of treatment on ataxia No effect e Complete regression of
ataxia under Acetazolamide
e Major improvement in
balance and episodes of ataxia
(from several daily to 1e2/week)
Epilepsy No No Generalized toniceclonic seizures Generalized tonic seizures
and complex-partial seizures
Generalized tonic seizures
e
u
r
o
p
e
a
n
jo
u
r
n
a
l
o
f
p
a
e
d
ia
t
r
ic
n
e
u
r
o
l
o
g
y
x
x
x
(x
x
x
x
)
x
x
x
6P
le
a
se
cite
th
is
a
rticle
a
s:
S
ch
w
a
rz
N
e
t
a
l.,
C
lin
ica
l
a
n
d
g
e
n
e
tic
sp
e
ctru
m
o
f
S
C
N
2
A
-a
sso
cia
te
d
e
p
iso
d
ic
a
ta
x
ia
,
E
u
ro
p
e
a
n
Jo
u
rn
a
l
o
f
P
a
e
d
ia
tric
N
e
u
ro
lo
g
y
,
h
ttp
s://d
o
i.o
rg
/1
0
.1
0
1
6
/j.e
jp
n
.2
0
1
9
.0
3
.0
0
1
A
g
e
a
t
se
iz
u
re
o
n
se
t
e
e
1
1
m
3
rd
p
o
st
n
a
ta
l
d
a
y
2
n
d
p
o
st
n
a
ta
l
d
a
y
C
u
rr
e
n
t
a
n
ti
-e
p
il
e
p
ti
c
m
e
d
ic
a
ti
o
n
a
n
d
d
o
sa
g
e
e
e
C
a
rb
a
m
a
ze
p
in
e
(1
6
m
g
/k
g
/d
)
S
o
d
iu
m
v
a
lp
ro
a
te
(3
4
m
g
/k
g
/d
a
y
),
P
h
e
n
y
to
in
(1
0
m
g
/k
g
/d
a
y
)
C
o
g
n
it
iv
e
st
a
tu
s/
d
e
v
e
lo
p
m
e
n
t
D
e
v
e
lo
p
m
e
n
ta
l
d
e
la
y
o
f
sp
e
e
ch
ID
ID
a
u
ti
sm
sp
e
ct
ru
m
d
is
o
rd
e
r
N
o
rm
a
l
N
o
rm
a
l
P
a
ti
e
n
t
2
0
(f
a
th
e
r
o
f
P
2
1
)
P
a
ti
e
n
t
2
1
(d
a
u
g
h
te
r
o
f
P
20
)
P
re
v
io
u
sl
y
p
u
b
li
sh
e
d
M
a
k
se
m
o
u
s
e
t
a
l.
,
2
0
1
8
(P
M
ID
:
3
0
3
1
4
2
9
5
)
M
a
k
se
m
o
u
s
e
t
a
l.
,
2
0
1
8
(P
M
ID
:
3
0
3
1
4
2
9
5
)
G
e
n
d
e
r,
a
g
e
M
,
3
1
y
F
,
8
y
P
a
th
o
g
e
n
ic
v
a
ri
a
n
t,
in
h
e
ri
ta
n
ce
c.
3
9
7
3
G
>
T
,
p
.V
1
3
2
5
F
d
e
n
ov
o
c.
3
9
7
3
G
>
T
,
p
.V
1
3
2
5
F
in
h
e
ri
te
d
fr
o
m
fa
th
e
r
A
g
e
a
t
a
ta
x
ia
o
n
se
t
1
4
y
e
a
rs
2
1
m
o
n
th
s
F
re
q
u
e
n
cy
o
f
e
p
is
o
d
e
s
In
te
rm
it
te
n
t,
u
p
to
a
fe
w
p
e
r
w
e
e
k
In
te
rm
it
te
n
t,
u
p
to
a
fe
w
p
e
r
w
e
e
k
D
u
ra
ti
o
n
o
f
si
n
g
le
e
p
is
o
d
e
o
f
a
ta
x
ia
N
A
N
A
T
ri
g
g
e
rs
fo
r
a
ta
x
ia
E
x
e
rt
io
n
,
m
in
o
r
h
e
a
d
tr
a
u
m
a
E
x
e
rt
io
n
,
m
in
o
r
h
e
a
d
tr
a
u
m
a
T
re
a
tm
e
n
t
fo
r
a
ta
x
ia
A
ce
ta
zo
la
m
id
e
(d
o
se
u
n
d
e
r
a
d
ju
st
m
e
n
t)
A
ce
ta
zo
la
m
id
e
(d
o
se
u
n
d
e
r
a
d
ju
st
m
e
n
t)
E
ff
e
ct
o
f
tr
e
a
tm
e
n
t
o
n
a
ta
x
ia
L
im
it
e
d
M
a
rg
in
a
l
E
p
il
e
p
sy
A
to
n
ic
se
iz
u
re
s
A
to
n
ic
se
iz
u
re
s
A
g
e
a
t
se
iz
u
re
o
n
se
t
1
4
y
e
a
rs
2
1
m
o
n
th
s
C
u
rr
e
n
t
a
n
ti
-e
p
il
e
p
ti
c
m
e
d
ic
a
ti
o
n
a
n
d
d
o
sa
g
e
N
o
n
e
N
o
n
e
C
o
g
n
it
iv
e
st
a
tu
s/
d
e
v
e
lo
p
m
e
n
t
S
o
m
e
le
a
rn
in
g
d
if
fi
cu
lt
ie
s
M
il
d
-m
o
d
e
ra
te
g
lo
b
a
l
d
e
v
e
lo
p
m
e
n
ta
l
d
e
la
y
A
E
D
¼
a
n
ti
-e
p
il
e
p
ti
c
d
ru
g
,
F
¼
fe
m
a
le
,
ID
¼
in
te
ll
e
ct
u
a
l
d
is
a
b
il
it
y
,
M
¼
m
a
le
,
m
¼
m
o
n
th
,
N
A
¼
n
o
t
a
v
a
il
a
b
le
,
w
¼
w
e
e
k
,
y
¼
y
e
a
r.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y x x x ( x x x x ) x x x 7
Please cite this article as: Schwarz N et al., Clinical and genetic spe
Paediatric Neurology, https://doi.org/10.1016/j.ejpn.2019.03.001The co-occurrence of epileptic seizures in patients with
pathogenic SCN2A variants is not surprising.4 Noteworthy,
SCN2A associated EA primarily affects patients with milder
cases of SCN2A associated epilepsy, whereas only two of our
patients showed severe developmental delay. Yet, EA may be
underestimated and insufficiently reported in patients with
SCN2A epileptic and developmental encephalopathy possibly
because ataxia is harder to identify in severely handicapped
patients. In addition, persistent ataxia is known as secondary
adverse event during medication with phenytoin,14,15 it is
therefore challenging to disentangle the causality between the
pathogenic SCN2A variant and ataxia in encephalopathic pa-
tients under multi-drug treatment. Four of our patients
showed divergent signs of intellectual impairment: while Pa-
tient 16 showed an IQ of 71 with particular impairment in her
speech development,5 Patient 17 showed traits of autism
spectrumdisorder. Given that this particular patient showed a
seizure onset at 11 months and based on previous reports,4,18
we assume that this particular variant (p.G1634D) may be a
pathogenic loss-of-function variant.
While epileptic seizures mostly occurred within the first
three months of life (12/18 patients), EA onset was earliest at
10 months of life. The most probable explanation is the
divergent expression of NaV1.2 withinmyelinated nerve fibers
compared to parallel fibers forming the axons of cerebellar
granule cells which project to cerebellar Purkinje cells. As
shown by Liao et al., NaV1.2 is expressed very early during
development in the hippocampal CA1 region,20 whereas its
cerebellar expression increases during postnatal development
in mice.8 The latest time point of EA onset was at 14 years of
age, the explanation for this heterogeneity regarding EA onset
remains unknown. Triggers for the onset of EA in this patient
were not identified. Genetic and environmental factors acting
as modifiers might influence the onset of paroxysmal events
such as EA and epilepsy.9,21
Treatment options for SCN2A associated EA remain insuf-
ficient. Our study shows that sodium channel blockers such as
phenytoine though beneficial for the treatment of neonatale/
early-onset SCN2A associated epilepsy4e are not as promising
for EA treatment as the treatment with acetazolamide. The
underlying mechanisms are not understood. Early-onset
SCN2A associated epileptic seizures are generally thought to
be caused by pathogenic gain-of-function SCN2A variants.
Given that pathogenic gain-of-function SCN2A variants can
lead to EA,10 we hypothesized that EA in these patients simi-
larly profits from treatment with sodium channel blockers as
their epilepsy does, but we could not confirm this in most of
the cases.
The only patient with a supposed loss-of-function variant
(patient 17) responded dramaticaly to acetazolamide imme-
diately after initiation of treatment.7 Acetazolamide was also
effective in patient 19 with a pathogenic variant that is known
to cause a gain-of-function effect (p.A263V).8 Thus, acetazol-
amide might represent a treatment option in SCN2A-associ-
ated EA irrespective of the type of pathogenic variant. While
two additional individuals (Patients 20 and 21) slightly
benefited from acetazolamide treatment, the majority (5/9)
did not respond to acetazolamide. While the differences in
acetazolamide dosages (4.3 mge30 mg/kg body weight/day)
may play an important role, there are also cases with higherctrum of SCN2A-associated episodic ataxia, European Journal of
Fig. 2 e Overview of the SCN2A pathogenic variants found in patients with episodic ataxia.
Fig. 1 e Onsets of epileptic seizures versus ataxia for all patients.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y x x x ( x x x x ) x x x8dosages (Patients 14 and 15) that did not respond to the
treatment. Of note, the latter were familial cases with a very
peculiar phenotype (no seizures, low frequency and long
duration of EA episodes, specific impairment of speech
development),5 for which EA treatment may be particularly
challenging. We would encourage caregivers to try treatment
with acetazolamide in SCN2A associated EA in dosages up to
30 mg/kg body weight/day (and maybe even higher). Given
that carbamazepine showed major improvement in one case
(Patient 5), this would be our second line treatment recom-
mendation for these patients, knowing that further studies
are needed to establish a reliable treatment regimen. Of note,
despite insufficient treatment alternatives, our data are
encouraging for the majority of the patients who showed an
unimpaired or only slightly impaired cognitive outcome (17/21
patients, i.e. 81%). This observation should be kept in mind
when treating and counseling patients with SCN2A-associated
EA.Please cite this article as: Schwarz N et al., Clinical and genetic spe
Paediatric Neurology, https://doi.org/10.1016/j.ejpn.2019.03.001Finally, we identified one mutational hotspot and one re-
gion within NaV1.2 encompassing several cases. 7/21 patients
harbored the same pathogenic gain-of-function variant
(p.A263V) that has previously been shown as mutational
hotspot for SCN2A-associated epilepsy.4 Though genotypee
phenotype correlations have been attempted for SCN2A,22
this particular pathogenic variant has been associated with a
wide range of epileptic phenotypes from self-limited disease
courses to epileptic encephalopathy, e.g., Ohtahara syn-
drome.4 6/7 patients in our cohort (p.A263V) showed neonatal-
onset seizures, one patient showed seizure onset at 2 months
of life. EA onset was comparable between patients, i.e., be-
tween 18 and 36 months. 5/7 patients showed a normal
development.
The second hotspot is located within the domain IV
affecting the S4 segment (p.G1634D) and the neighboring
cytoplasmic loop linking S4 and S5 (p.L1650P in three familial
cases, plus p.F1651C). The S4 segment represents the voltagectrum of SCN2A-associated episodic ataxia, European Journal of
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y x x x ( x x x x ) x x x 9sensor of each domainwhich plays a crucial role for the gating
of NaV1.2.
23 The voltage sensor and the cytoplasmic loop be-
tween S4 and S5 are involved in the inactivation of the
channel.24,25 The pathogenic variant p.L1650P found in the
three familial cases of EA e lacking epileptic seizures e has
been described in a patient with epileptic encephalopathy,26
emphasizing the challenge in genotypeephenotype correla-
tions. A patient with a pathogenic de novo SCN2A missense
variant (p.L1660W) affecting this cytoplasmic loop was
described with recurrent encephalopathic episodes of which
at least one might have been an episode of ataxia.27 Finally, a
pathogenic variant in the homologous gene SCN8A at the
exact same position as in our three familial cases was
described in a patient with epileptic encephalopathy.28 These
data emphasize the pathophysiologic importance of this re-
gion for SCN2A-associated disorders.
In conclusion, SCN2A-associated EA represents a rare,
though potentially underestimated disorder in which a phar-
macological attempt with acetazolamide or a sodium channel
blocker should be performed.Funding
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